Zydus Lifesciences Novel CKD Drug Desidustat Receives Regulatory Approval in China

zydus
Image Courtesy: zydus

Zydus Lifesciences Limited has announced that its innovative drug, Desidustat, has received approval from China’s National Medical Products Administration (NMPA) for the treatment of anaemia associated with chronic kidney disease (CKD). The approval marks a significant milestone in expanding access to advanced therapies for CKD patients in one of the world’s largest pharmaceutical markets.

The drug has been licensed to CMS International Development and Management Limited, a wholly owned subsidiary of China Medical System Holdings Limited, which secured exclusive commercialization rights from Zydus in 2020. With this approval, CMS will lead the introduction and distribution of the therapy across China.

Desidustat is an orally administered therapy belonging to a new class of drugs known as Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors (HIF-PHI). It is designed to address anaemia in CKD patients by stimulating the body’s natural mechanisms for red blood cell production. In patients with impaired kidney function, the production of erythropoietin—a hormone critical for red blood cell formation—is reduced, often resulting in anaemia. Desidustat works by increasing endogenous erythropoietin levels, lowering hepcidin, and improving iron availability, thereby supporting effective erythropoiesis.

The approval comes at a time when there is a significant unmet need for effective CKD-related anaemia treatments in China. The country is estimated to have more than 120 million individuals affected by chronic kidney disease. Anaemia is a common and progressively worsening complication across all stages of CKD, with prevalence rates increasing sharply as the disease advances. Despite existing therapies, treatment outcomes—particularly among non-dialysis patients—remain suboptimal, highlighting the need for more effective and accessible solutions.

Desidustat’s oral formulation is expected to improve patient compliance compared to traditional injectable therapies, making it a convenient and patient-friendly option. The therapy has already demonstrated strong clinical acceptance in India, where it is marketed under the brand name Oxemia. Since its launch in 2022, the drug has been used to treat over 100,000 CKD patients, underscoring its potential to address large-scale treatment gaps.

Zydus Lifesciences emphasized that the approval reflects its continued focus on developing innovative therapies that improve patient outcomes globally. The collaboration with CMS is expected to accelerate access to the drug across Greater China, supporting better disease management and quality of life for patients.

Zydus is a global, innovation-driven life sciences company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare solutions. With a workforce of over 29,000 employees, including a strong research and development team, the company continues to advance new therapies across multiple therapeutic areas, including vaccines, biologics, and novel chemical entities.

CMS, a leading pharmaceutical platform company, focuses on bridging innovation and commercialization by advancing clinical research and ensuring efficient market access for innovative therapies. The partnership between Zydus and CMS represents a strategic alignment aimed at addressing critical healthcare needs through advanced scientific solutions.